Promega Corporation

Neuroprotection: Understanding the Modus Operandum of Glutamate Excitotoxicity

  • Share
  • Print
  • Email
  • Download PDF
  • Article
  • Comments & Ratings

Abstract

This review describes research using the Promega BDNF Emax® ImmunoAssay System in a continuous medium-withdrawal method for measuring BDNF release from NMDA-treated neurons. This method was initially developed by Ann M. Marini and colleagues in 1998 in a landmark paper for ELISA-based neurotrophin detection.

Cell Notes 19, 6–7.

Publication Date: 2007

Prefer a different language?

Your country is set to Brazil. Your language is set to Português. Please select the language that will best suit your needs:

This is correct, continue to site »

I need additional help

  • Warning
  • It appears that you have Javascript disabled. Our website requires Javascript to function correctly. Please enable Javascript to experience our website.